Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 4/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | NQO2 | P16083 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3209325 | 0.83 | APP (0.40) | APPCA12CA1CA2CA4 | |
| SCHEMBL15389999 | 0.79 | ALDH1A1 (0.39) | — | |
| SCHEMBL27675673 | 0.79 | ALDH1A1 (0.33) | — | |
| SCHEMBL6200727 | 0.78 | TSPO (0.41) | CA12CA1CA2CA7CA9 | |
| SCHEMBL27463249 | 0.77 | — | — | |
| SCHEMBL27588573 | 0.77 | HTR7 (0.44) | APPCA12CA1CA2CA4 | |
| SCHEMBL27650969 | 0.76 | ALDH1A1 (0.34) | — | |
| SCHEMBL8674 | 0.75 | CA2 (0.46) | CA12CA1CA2CA4CA7 | |
| SCHEMBL2776293 | 0.75 | KDM4E (0.32) | — | |
| SCHEMBL6315253 | 0.75 | ALDH1A1 (0.37) | CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109851602-B | 14-deoxy-11,12-dehydro-8,12-epoxy-andrographolide and 15-substituted derivatives thereof | 郑州大学 | 2023-04-11 | — | — | CN | claimed |
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-05-31 | — | — | US | claimed |
| EP-3294729-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-03-21 | — | — | EP | claimed |
| CN-107635986-A | Substituted quinoxaline derivatives | 赛尔维他股份公司 | 2018-01-26 | — | — | CN | claimed |
| WO-2016180536-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2016-11-17 | — | — | WO | claimed |
| US-9994566-B2 | Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryl or heteroaryl, preparation method thereof and pharmaceutical use thereof | SHENYANG SUNSHINE PHARMACEUTICAL CO. LTD. (CN) | 2018-06-12 | — | — | US | disclosed |
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-05-31 | — | — | US | disclosed |
| US-20180118738-A1 | COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYL OR HETEROARYL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | SHENYANG SUNSHINE PHARMACEUTICAL CO., LTD. (CN) | 2018-05-03 | — | — | US | disclosed |
| EP-3294729-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-03-21 | — | — | EP | disclosed |
| EP-3287456-A1 | COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYL OR HETEROARYL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | Shenyang Sunshine Pharmaceutical Co., Ltd. (CN) | 2018-02-28 | — | — | EP | disclosed |
| WO-2016180536-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2016-11-17 | — | — | WO | disclosed |
| EP-0945440-B1 | AMINOPYRAZOLE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2004-05-26 | — | — | EP | disclosed |
| US-6180653-B1 | EATING DISORDERS; DIETETICS; ANTIDIABETIC AGENTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2001-01-30 | — | — | US | disclosed |
| US-6166038-A | Aminopyrazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2000-12-26 | — | — | US | disclosed |
| US-6057335-A | Pyrazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2000-05-02 | — | — | US | disclosed |
| US-6043246-A | Urea derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2000-03-28 | — | — | US | disclosed |
| EP-0955293-A1 | NOVEL UREA DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-11-10 | — | — | EP | disclosed |
| EP-0945440-A1 | AMINOPYRAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-09-29 | — | — | EP | disclosed |
| EP-0945439-A1 | NOVEL AMINOPYRAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-09-29 | — | — | EP | disclosed |
| EP-0945438-A1 | PYRAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118738-A1 | COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYL OR HETEROARYL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | HIF1AN, EGLN3, EGLN2 | APP 3032/4885CA12 4086/4885CA1 3786/4885 |
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | BRCA1, NQO2, NQO1 | APP 4554/4885CA12 4841/4885CA1 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.